FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

A Framework for Assessing the Impact of Accelerated Approval

FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma

Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors

FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

header-info

Jul, 18, 2022

On July 14, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors.